ATE429931T1 - Zusammensetzungen zur hemmung der proliferation und infiltration von gehirntumorzellen durch expression der ampa-typ glutamat-rezeptor- untereinheit - Google Patents

Zusammensetzungen zur hemmung der proliferation und infiltration von gehirntumorzellen durch expression der ampa-typ glutamat-rezeptor- untereinheit

Info

Publication number
ATE429931T1
ATE429931T1 AT03784615T AT03784615T ATE429931T1 AT E429931 T1 ATE429931 T1 AT E429931T1 AT 03784615 T AT03784615 T AT 03784615T AT 03784615 T AT03784615 T AT 03784615T AT E429931 T1 ATE429931 T1 AT E429931T1
Authority
AT
Austria
Prior art keywords
tumor cells
brain tumor
glutamate receptor
ampa
infiltration
Prior art date
Application number
AT03784615T
Other languages
English (en)
Inventor
Seiji Ozawa
Shogo Ishiuchi
Original Assignee
Japan Science & Tech Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science & Tech Agency filed Critical Japan Science & Tech Agency
Application granted granted Critical
Publication of ATE429931T1 publication Critical patent/ATE429931T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03784615T 2002-08-08 2003-08-08 Zusammensetzungen zur hemmung der proliferation und infiltration von gehirntumorzellen durch expression der ampa-typ glutamat-rezeptor- untereinheit ATE429931T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002232086A JP4175846B2 (ja) 2002-08-08 2002-08-08 Ａｍｐａ型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制
PCT/JP2003/010143 WO2004014433A1 (ja) 2002-08-08 2003-08-08 Ａｍｐａ型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制

Publications (1)

Publication Number Publication Date
ATE429931T1 true ATE429931T1 (de) 2009-05-15

Family

ID=31711765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784615T ATE429931T1 (de) 2002-08-08 2003-08-08 Zusammensetzungen zur hemmung der proliferation und infiltration von gehirntumorzellen durch expression der ampa-typ glutamat-rezeptor- untereinheit

Country Status (8)

Country Link
US (1) US20060128645A1 (de)
EP (1) EP1552852B1 (de)
JP (1) JP4175846B2 (de)
AT (1) ATE429931T1 (de)
CA (1) CA2494063C (de)
DE (1) DE60327449D1 (de)
ES (1) ES2324780T3 (de)
WO (1) WO2004014433A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220825A1 (en) 2002-03-29 2003-10-13 Yamanouchi Pharmaceutical Co., Ltd. Remedy for glioblastoma
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
KR101522918B1 (ko) 2009-05-29 2015-05-27 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 유도체를 포함하는 주사용 멜팔란 조성물 및 이의 제조 및 사용 방법
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
JP6371063B2 (ja) * 2013-01-30 2018-08-08 国立大学法人 岡山大学 悪性腫瘍の検査方法および抗腫瘍剤
EP3829567A4 (de) * 2018-07-27 2022-05-04 With Great Power, LLC Klinische verfahren und pharmazeutische zusammensetzungen mit ampa-rezeptor-antagonisten zur behandlung von glioblastom und anderen karzinomen
CN111269939A (zh) * 2019-07-16 2020-06-12 湖南大学深圳研究院 稳定表达AMPA受体GluR1/GluR2细胞株及其构建方法
WO2022235810A1 (en) * 2021-05-04 2022-11-10 Tukey David A biological entity for treating brain cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265528T1 (de) * 1989-10-27 2004-05-15 Salk Inst For Biological Studi Rezeptorverbindungen von glutamin und herstellung

Also Published As

Publication number Publication date
EP1552852A4 (de) 2006-11-29
EP1552852B1 (de) 2009-04-29
EP1552852A1 (de) 2005-07-13
US20060128645A1 (en) 2006-06-15
DE60327449D1 (de) 2009-06-10
CA2494063A1 (en) 2004-02-19
WO2004014433A1 (ja) 2004-02-19
JP4175846B2 (ja) 2008-11-05
JP2004067627A (ja) 2004-03-04
CA2494063C (en) 2011-03-15
ES2324780T3 (es) 2009-08-14

Similar Documents

Publication Publication Date Title
Sander et al. Histamine H3 receptor antagonists go to clinics
Amargós-Bosch et al. Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex
Abbas et al. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
DE60215028D1 (de) Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
DE60327449D1 (de) Zusammensetzungen zur hemmung der proliferation und infiltration von gehirntumorzellen durch expression der ampa-typ glutamat-rezeptor-untereinheit
DE602005024279D1 (de) 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren
DK1263752T3 (da) LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf
CY1111956T1 (el) C-met διαμορφωτες και μεθοδοι χρησης
MXPA05001277A (es) 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MEP48108A (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
ATE428694T1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid- derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
ATE539768T1 (de) Kombinationen von metabotropische-glutamat- rezeptor-antagonisten und ihre verwendung zur behandlung von suchtstörungen
TW200636076A (en) Method for measuring resistance or sensitivity to docetaxel
DE60327375D1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
ATE282625T1 (de) Gaba-c-rezeptor-antagonisten zur stimulation des erinnerungsvermögens
Bayarri et al. Melatonin binding sites in the brain of European sea bass (Dicentrarchus labrax)
DE602005027322D1 (de) Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
DE602004013427D1 (de) Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
AR057823A1 (es) Compuestos quimicos derivados de quinazolina, un metodo para su preparacion y composicion farmaceutica
DE602005018381D1 (de) 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors
DE602004007633D1 (de) Substituierte piperidin- und piperazin-derivate als melanocortin-4 rezeptor modulatoren
PE20060498A1 (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa i(epsilon)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties